MedTech News
.................... by Andrew Celentano

Experimental mRNA therapy promotes repair after heart attack damage
Scientists have developed a treatment that ‘reawakens’ heart muscle cells so they start to divide and help repair damaged muscle.

A single CRISPR infusion lowers blood fats in monkeys for three years
In a new CRISPR experiment, a single infusion of a gene-editing treatment kept triglyceride levels low in monkeys for three years.

Blocking excess scarring helps prevent heart failure development
Researchers have successfully prevented the development of severe heart failure in a mouse model of heart attack by blocking a protein that triggers the formation of excessive scar tissue.

Tandem Diabetes Care Receives Health Canada Approvals for t:slim X2 Insulin Pump
Tandem Diabetes Care has announced receipt of Health Canada approval of a license amendment for the t:slim X2 insulin pump with Control-IQ+ automated insulin delivery technology.

Tandem’s Mobi pump wins FDA clearance for 7-day tubeless wearable set
Tandem Diabetes Care (Nasdaq: TNDM) has secured an FDA clearance for a tubeless version of its miniaturized automated insulin delivery system.

Bracco and Avicenna.AI Announce FDA Clearance for UPTUNITY™ | Aneurysm, a New AI-Enabled Software for Brain Aneurysm Detection and Assessment
Developed in collaboration with Avicenna.AI, the newly FDA-cleared technology introduces UPTUNITY™, Bracco’s new portfolio of AI-enabled clinical decision support solutions.

Small RNA from surrounding cells promotes triple-negative breast cancer growth
A research team led by Dr. Hyun-Soo Cho at the Korea Research Institute of Bioscience and Biotechnology (KRIBB), in collaboration with Professor Keun Hur’s team at Kyungpook National University, has identified how miR-1290, a type of microRNA transferred from fibroblasts surrounding tumors, promotes the growth of triple-negative breast cancer cells.

Combination therapy overcomes treatment resistance in breast cancer models
A combination approach successfully overcame treatment resistance and led to durable responses in preclinical models of advanced breast cancer.